<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154718">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916291</url>
  </required_header>
  <id_info>
    <org_study_id>Propess in PROM or GA&lt;38</org_study_id>
    <nct_id>NCT01916291</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Dinoprostone(Propess)in the Women With Premature Rupture of Membrane or Gestational Age &lt;38</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dinoprostone(propess) is commonly used for induction of labor in the pregnant women who has
      intact membrane after 38weeks of gestational age. The investigators study safety and
      efficacy of dinoprostone in the pregnant women with premature rupture of membrane or
      GA&lt;38weeks
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Induction success rate after propess insertion</measure>
    <time_frame>Day 1 after propess insertion</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of prostaglandinE</measure>
    <time_frame>at delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Induction of Labor</condition>
  <arm_group>
    <arm_group_label>Propess insertion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propess insertion</intervention_name>
    <arm_group_label>Propess insertion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women who admitted for induction of labor

          -  Bishop score &lt;= 6

        Exclusion Criteria:

          -  Contraindication to induction of labor

          -  Active labor

          -  Vaginal bleeding, unknown origin

          -  Hypersensitive to Prostaglandin E

          -  History of asthma, glaucoma

          -  Infection (birth canal)

          -  Placental abruption

          -  Multiparity(&gt;5)

          -  Pelvic inflammatory disease

          -  Heart, lung, kidney disease

          -  Multiple pregnancy

          -  Major anomaly

          -  Fetal distress before induction of labor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joong Shin Park, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eunjin Kim, MD</last_name>
    <phone>82-10-7748-4268</phone>
    <email>kejin1000@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joong Shin Park, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sun Min Kim , MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>July 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
